Decernotinib: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Overview of the drug Decernotinib}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Decernotinib.svg | |||
| image_size = 200px | |||
| image_alt = Chemical structure of Decernotinib | |||
}} | |||
'''Decernotinib''' is a [[Janus kinase inhibitor]] (JAK inhibitor) that has been investigated for its potential use in the treatment of [[rheumatoid arthritis]]. It specifically targets the JAK3 enzyme, which plays a crucial role in the signaling pathways of various cytokines involved in the immune response. | |||
Decernotinib | ==Mechanism of Action== | ||
Decernotinib functions by selectively inhibiting the activity of the [[Janus kinase 3|JAK3]] enzyme. JAK3 is associated with the common gamma chain of cytokine receptors, which are critical for the signaling of several interleukins, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. By inhibiting JAK3, decernotinib disrupts these signaling pathways, leading to a reduction in the inflammatory response that characterizes autoimmune diseases such as rheumatoid arthritis. | |||
== Clinical | ==Clinical Development== | ||
Decernotinib has undergone various phases of clinical trials to assess its efficacy and safety in patients with rheumatoid arthritis. These trials have focused on its ability to reduce the symptoms of the disease, such as joint pain and swelling, and to improve overall physical function. | |||
==Pharmacokinetics== | |||
The pharmacokinetic profile of decernotinib includes its absorption, distribution, metabolism, and excretion. It is administered orally and has been shown to have a predictable absorption pattern. The drug is metabolized primarily in the liver and excreted through both renal and fecal pathways. | |||
== | ==Side Effects== | ||
Common side effects observed in clinical trials of decernotinib include [[headache]], [[nausea]], and [[upper respiratory tract infection]]. As with other JAK inhibitors, there is a potential risk of serious infections due to the suppression of the immune system. | |||
==Potential Applications== | |||
While primarily investigated for rheumatoid arthritis, the mechanism of action of decernotinib suggests potential applications in other autoimmune diseases where JAK3 plays a role. These could include conditions such as [[psoriasis]] and [[inflammatory bowel disease]]. | |||
== | ==Related pages== | ||
* [[Rheumatoid arthritis]] | * [[Rheumatoid arthritis]] | ||
* [[ | * [[Janus kinase inhibitors]] | ||
* [[Autoimmune disease]] | |||
[[Category:Janus kinase inhibitors]] | |||
[[Category:Experimental drugs]] | [[Category:Experimental drugs]] | ||
<gallery> | |||
File:Decernotinib.svg|Decernotinib | |||
</gallery> | |||
Latest revision as of 00:59, 20 February 2025
Overview of the drug Decernotinib
| Decernotinib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Decernotinib is a Janus kinase inhibitor (JAK inhibitor) that has been investigated for its potential use in the treatment of rheumatoid arthritis. It specifically targets the JAK3 enzyme, which plays a crucial role in the signaling pathways of various cytokines involved in the immune response.
Mechanism of Action[edit]
Decernotinib functions by selectively inhibiting the activity of the JAK3 enzyme. JAK3 is associated with the common gamma chain of cytokine receptors, which are critical for the signaling of several interleukins, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. By inhibiting JAK3, decernotinib disrupts these signaling pathways, leading to a reduction in the inflammatory response that characterizes autoimmune diseases such as rheumatoid arthritis.
Clinical Development[edit]
Decernotinib has undergone various phases of clinical trials to assess its efficacy and safety in patients with rheumatoid arthritis. These trials have focused on its ability to reduce the symptoms of the disease, such as joint pain and swelling, and to improve overall physical function.
Pharmacokinetics[edit]
The pharmacokinetic profile of decernotinib includes its absorption, distribution, metabolism, and excretion. It is administered orally and has been shown to have a predictable absorption pattern. The drug is metabolized primarily in the liver and excreted through both renal and fecal pathways.
Side Effects[edit]
Common side effects observed in clinical trials of decernotinib include headache, nausea, and upper respiratory tract infection. As with other JAK inhibitors, there is a potential risk of serious infections due to the suppression of the immune system.
Potential Applications[edit]
While primarily investigated for rheumatoid arthritis, the mechanism of action of decernotinib suggests potential applications in other autoimmune diseases where JAK3 plays a role. These could include conditions such as psoriasis and inflammatory bowel disease.
Related pages[edit]
-
Decernotinib
